HOME >> MEDICINE >> NEWS
Combination vaccine produces lower immune response than vaccines administered separately

A combination vaccine developed to reduce the number of vaccines infants receive appears to provide less immunity than the vaccines administered individually, according to a study in the April 13 issue of JAMA.

The development of immunogenic vaccines against major diseases of childhood has dramatically decreased the rates of invasive disease, according to background information in the article. Since the introduction of a monovalent serogroup C meningococcal glycoconjugate vaccine (MenC) into the United Kingdom routine immunization schedule in November 1999, group C meningococcal disease has decreased by 87 percent in the ages targeted for vaccination, with estimated vaccine efficacy of 90 percent. Within 2 years of the introduction of a 7-valent pneumococcal glycoconjugate vaccine into the recommended infant schedule in the United States, there was a 69 percent reduction in culture-positive invasive pneumococcal disease in children younger than 2 years.

The advent of these efficacious and safe vaccines has increased pressure on crowded infant immunization schedules. Infants in the United States receive up to 20 separate vaccine injections over 5 immunization encounters at ages 2, 4, 6, 12, and 18 months to protect against disease due to hepatitis B, diphtheria, tetanus, pertussis, polio, measles, mumps, rubella, varicella, H influenzae type b, and pneumococcus. The inclusion of MenC would add a further 3 to 4 doses to the U.S. regimen. The development of combination vaccines has become a priority. The combining of pneumococcal and meningococcal conjugate vaccines has the potential to spare U.S. infants up to 4 extra injections by age 18 months and to decrease parental and clinician concerns about the number of vaccinations in early childhood.

Jim P. Buttery, F.R.A.C.P., formerly of the University of Oxford, Churchill Hospital, Headington, Oxford, U.K., and colleagues conducted a study to determine the immunogenicity and safety of a combinati
'"/>

Contact: Jim P. Buttery, F.R.A.C.P.
jim.buttery@rch.org.au
JAMA and Archives Journals
12-Apr-2005


Page: 1 2

Related medicine news :

1. Combination treatment stymies breast cancer growth
2. Combination therapy spares some head and neck patients from surgery
3. Combination of personality traits increases risk for heart disease
4. Combination therapy may improve survival for pancreatic cancer
5. Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection
6. Combination of three new, high-powered MRI systems at PENN is a first in the US
7. Dynamic duo: Combination therapy reverses type 1 diabetes
8. Combination of interventions can substantially reduce incidence of malaria in people with HIV
9. Combination therapy improves AIDS-related lymphoma outcome
10. Combination treatment for brain cancer not detrimental to patients quality of life
11. Combination microbicides protect monkeys against HIV-like virus

Post Your Comments:
(Date:7/7/2015)... ... July 07, 2015 , ... The Immune Deficiency Foundation (IDF) ... community using its IDF ePHR, an electronic personal health record powered by Get ... easily track their health information, including symptoms, diagnoses, medications, infusions and other critical ...
(Date:7/7/2015)... ... 07, 2015 , ... Parents and guardians of teenagers or young adults will ... holistic treatment center for drug and alcohol abuse located in Southwest Michigan. A recently ... shown a significant increase in the “club drug” use among high school seniors. The ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... of telemedicine programs in communities throughout Georgia, announces the launch of the first ... rural communities of Hancock County, GA. The new program will not only provide ...
(Date:7/7/2015)... NH (PRWEB) , ... July ... ... integrated, full-service public relations, marketing, and creative design firm, today announced that ... regional public relations and social media campaign, content strategy, and marketing launch ...
(Date:7/7/2015)... Horsham, PA (PRWEB) , ... July 07, 2015 ... ... seasoned financial executive Ellen Purdy as the company’s new Chief Financial Officer, effective ... financial and leadership experience in companies ranging from a multi-billion dollar, global chemical ...
Breaking Medicine News(10 mins):Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:A Forever Recovery Releases New Information on “Club Drugs” and Tips for Parents of Teens and Young Adults 2Health News:Georgia Partnership for TeleHealth prepares to Launch First Ambulance Telemedicine Solution in Georgia 2Health News:TimberNook Selects Calypso Communications for PR, Social Media and Content Strategy 2Health News:Office Practicum Announces new CFO 2
(Date:7/7/2015)... SHENZHEN, China , July 7, 2015 /PRNewswire/ -- ... ), a leading developer, manufacturer and marketer of ... to acquire the remaining stake in Wuhan Dragonbio ... million. Dragonbio is a domestic ... joint and other surgical products. Prior to today,s ...
(Date:7/7/2015)... 2015 EnteroMedics Inc. (NASDAQ: ETRM ), ... technology to treat obesity, metabolic diseases, and other gastrointestinal ... offering of 32,000,000 units. Each unit consists of one share ... purchase one share of common stock at a purchase ... units in the offering would result in them beneficially ...
(Date:7/7/2015)... July 7, 2015 Oasmia ... of drugs within human and veterinary oncology, today ... in the United States , ... leading companion animal therapeutic.      (Logo: ... ) , Paccal Vet-CA1 was ...
Breaking Medicine Technology:Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 3Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3Oasmia Pharmaceutical Launches US Brand and Sales Platform 2
Cached News: